High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2)
Status:
Completed
Trial end date:
2012-07-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish the pharmacokinetics of PEG-Intron, administered at
a dose of 6 μg/kg/week for 8 weeks (induction treatment), followed by a dose of 3 μg/kg/week
for up to 252 weeks (maintenance treatment), in patients with high risk melanoma.